- Home
- INKT vs ASPS Comparison
INKT vs ASPS Comparison
Compare INKT & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ASPS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.6M | 70.7M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | INKT | ASPS |
|---|---|---|
| Price | $11.67 | $7.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $8.00 |
| AVG Volume (30 Days) | ★ 23.7K | 13.6K |
| Earning Date | 05-15-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $942,213,000.00 |
| Revenue This Year | N/A | $9.17 |
| Revenue Next Year | N/A | $24.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.01 | $4.30 |
| 52 Week High | $76.00 | $15.96 |
Technical Indicators
Market Signals| Indicator | INKT | ASPS |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 54.23 |
| Support Level | $10.82 | $6.02 |
| Resistance Level | $12.61 | $7.35 |
| Average True Range (ATR) | 0.66 | 0.42 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 40.74 | 46.29 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.